NICE’s 2025 Guidance on Obesity Management Support

By João L. Carapinha

August 6, 2025

NICE’s August 2025 quality standard on obesity management support emphasizes the need for sustained support after weight management interventions. The guidance formalizes specific expectations for recording, support, and follow-up. It targets adults, children, and key groups like people with long-term conditions and learning disabilities.

Prioritizing Continuous Support After Treatment

The standard highlights persistent challenges in long-term obesity management. Most people regain weight after stopping medicines or structured interventions. NICE requires healthcare services to provide continued advice on diet, physical activity, and behavior change. Annual follow-up is emphasized for adults with long-term conditions and those discharged from bariatric surgery. Individuals stopping anti-obesity medications or finishing behavioral programs should receive structured advice and relapse prevention strategies. They should also have access to ongoing support for at least a year. These provisions aim to mitigate weight regain and “weight cycling.”

Tailored Strategies for Diverse Populations

The updated guidance introduces nuanced recording of BMI and waist-to-height ratio for adults with long-term conditions. It adjusts for ethnicity and age. Specific provisions ensure opportunistic BMI recording for children over two during healthcare contacts. The standard mandates tailored access and support for people with learning disabilities. Commissioners and providers must make reasonable adjustments and co-produce pathways with patients and carers. The framework calls for transparent documentation of available local and national interventions.

Transforming Health Economics and Care Strategies

This quality standard will shape commissioning and evaluation of obesity management support. By codifying long-term follow-up as a core measure, NICE has redefined service expectations. In health economics, this approach will require modeling long-term maintenance and relapse prevention. These requirements may alter cost-effectiveness profiles for pharmacotherapies and behavioral interventions. The need for service directories may increase demand for digital infrastructure.

In sum, NICE’s new standard elevates expectations for continuity and personalization in obesity care. It aligns NHS practice with evolving international best practices. This presents a new paradigm for measuring clinical and economic value in weight management. For additional insights on sustaining weight loss after treatment, explore further here.

Reference url

Recent Posts

Advancing Tarlatamab for Small Cell Lung Cancer Treatment

By HEOR Staff Writer

March 30, 2026

New Treatment Option for Relapsed Extensive-Stage Small Cell Lung Cancer Tarlatamab small cell lung therapy has received a positive opinion from the European Medicines Agency (EMA) for marketing authorisation. The bispecific T-cell engager is recommended as monotherapy ...
FDA Approves Once-Weekly Basal Insulin Awiqli® for Type 2 Diabetes Management
The US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) as the once-weekly basal insulin for adults with type 2 diabetes. This approval marks a major advancement in reducing treatment burden by decreasing basal insulin injections from seven to one per week.
Inflation Reduction Act Impact on Clinical Trial Investment Trends

By João L. Carapinha

March 26, 2026

The Inflation Reduction Act Impact is becoming evident in early data on industry-sponsored clinical trials. A recently published JME article examines how the Drug Price Negotiation Program (DPNP) introduced by the IRA may be altering investment incentives for biopharmaceutical innovation.